financetom
Business
financetom
/
Business
/
Nxu Gets Shareholder Approval for Merger With Verde Bioresins; Shares Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nxu Gets Shareholder Approval for Merger With Verde Bioresins; Shares Rise
Feb 12, 2025 7:36 AM

10:12 AM EST, 02/12/2025 (MT Newswires) -- Nxu (NXU) and Verde Bioresins said Wednesday that Nxu shareholders have voted to approve their merger.

The merger is expected to be completed in March, subject to the satisfaction of other closing conditions, the companies said. When completed, pre-merger Verde stockholders will own 95% of the combined company while pre-merger Nxu shareholders will hold about 5%.

Nxu shares were rising 50% in recent Wednesday trading.

Price: 0.41, Change: +0.14, Percent Change: +50.35

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Netflix Insider Sold Shares Worth $2,945,315, According to a Recent SEC Filing
Netflix Insider Sold Shares Worth $2,945,315, According to a Recent SEC Filing
May 26, 2025
04:13 AM EDT, 05/05/2025 (MT Newswires) -- Spencer Adam Neumann, Chief Financial Officer, on May 01, 2025, sold 2,601 shares in Netflix ( NFLX ) for $2,945,315. Following the Form 4 filing with the SEC, Neumann has control over a total of 3,691 common shares of the company, with 3,691 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1065280/000106528025000229/xslF345X05/wk-form4_1746232096.xml ...
Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study
Nanobiotix Says Potential Pancreatic Cancer Treatment Extends Survival in Phase 1 Study
May 26, 2025
04:09 AM EDT, 05/05/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study. A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months,...
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial
Recursion Pharmaceuticals Reports Promising Early Results for Familial Adenomatous Polyposis Drug Trial
May 26, 2025
04:10 AM EDT, 05/05/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Sunday early results from a phase 1/2 trial of its drug REC-4881 for Familial Adenomatous Polyposis showed a median reduction in polyp burden of 43% after 13 weeks among six patients who were evaluated. The company said five patients saw polyp reductions between 31% and 82%, while...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved